In conclusion, PSMA-PET seems superior compared to many metabolic radioligands tested in prostate cancer although the potential of some ligands such as 18F-FDG-PET should be evaluated in some subtypes of prostate cancers and PSMA-low prostate tumors. This evidence concerns the gene FOLH1 and prostate carcinoma.